Sinovac Biotech Ltd
SVA Nasdaq· Pharmaceutical Preparations
Last close · Mar 21, 2025
$6.47
KIRA · Stoqly’s AI analyst, in plain words
- Sinovac Biotech Ltd had $386M of revenue in fiscal 2025, up 6.8% on the year before. Over five years, revenue changed −5.4% a year on average.
- Its operating margin was −127.0%, up 12.9 pts: of every 100 in sales, about −127 is left after running the business.
- Sinovac Biotech Ltd lost $199M in fiscal 2025.
- Free cash flow was −$561M in fiscal 2025, −145.4% of revenue. At that burn of $561M a year, its $6.0B of cash and short-term investments would last about 10.6 years.
- Sinovac Biotech Ltd returned $3.5B to shareholders in fiscal 2025. The diluted share count rose 0.0%.
- Sinovac Biotech Ltd has $5.5B more cash than debt.
Market cap
$465M
P/E
—
Revenue
$386M
Net income
−$199M
Free cash flow
−$561M
Operating margin
−127.0%
Sinovac Biotech Ltd in 30 seconds · fiscal 2025
Are sales growing?
+6.8%
Yes. Sales grew 6.8% last year.
Does it make a profit?
−51.5%
No. It lost money last year.
How long would its cash last?
10.6 yrs
Comfortably. It burns $561M a year and holds $6.0B, about 10.6 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sinovac Biotech Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Jun 5, 2026
- Legal name
- SINOVAC BIOTECH LTD
- CIK
- 0001084201
Sinovac Biotech Ltd · SVA · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $19.4B | $1.5B | $470M | $361M | $386M |
| Revenue growth | 3,692.5% | −92.4% | −68.1% | −23.1% | 6.8% |
| Gross margin | 94.9% | 55.3% | 68.8% | 61.1% | 67.9% |
| Operating margin | 91.0% | −34.5% | −151.9% | −139.9% | −127.0% |
| Net income | $8.1B | $14.5M | −$13.5M | $40.7M | −$199M |
| Net margin | 41.9% | 1.0% | −2.9% | 11.3% | −51.5% |
| Diluted EPS | $113.44 | $0.20 | −$0.19 | $1.27 | −$0.83 |
| Cash | |||||
| Cash from operations | $15.3B | −$798M | $139M | −$56.9M | −$512M |
| Capital expenditure | $594M | $314M | $156M | $96.0M | $48.9M |
| Free cash flow | $14.7B | −$1.1B | −$17.5M | −$153M | −$561M |
| FCF margin | 76.1% | −75.5% | −3.7% | −42.3% | −145.4% |
| Dividends paid | $1.9B | $247M | $328M | $947M | $3.5B |
| Share count change | −37.0% | 0.2% | 0.1% | 0.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $13.4B | $10.5B | $11.0B | $9.9B | $6.0B |
| Debt incl. finance leases | $15.8M | $11.8M | $254M | $376M | $495M |
| Shareholders' equity | $9.0B | $8.5B | $8.3B | $8.3B | $4.4B |
| Net debt / EBITDA | −0.8x | — | — | — | — |
| Current ratio | 5.9x | 9.0x | 9.0x | 7.3x | 4.6x |
| Returns and quality | |||||
| Return on equity | 166.8% | 0.2% | −0.2% | 0.5% | −3.1% |
| Return on tangible equity | 90.3% | 0.2% | −0.2% | 1.1% | −1.4% |
| Piotroski F-score | 9 | 3 | 3 | 2 | 3 |
| Altman Z'' | 16.2 | 11.0 | 10.7 | 10.7 | 7.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sinovac Biotech Ltd · SVA · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.47 a share, the company is worth $465M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001084201). Latest version: stoqly.net/companies/sva. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.